Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.66 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7199438 | 0.83 | ATM (0.65) | MTNR1AATMTDP1KDM4E | |
| SCHEMBL22758120 | 0.83 | MTNR1A (0.51) | MTNR1AP2RX7ATMCDYLKDM4E | |
| SCHEMBL30258002 | 0.81 | IAPP (0.56) | MTNR1AP2RX7NQO2CDYLTDP1 | |
| SCHEMBL4070601 | 0.81 | IAPP (0.56) | MTNR1AP2RX7NQO2CDYLTDP1 | |
| SCHEMBL9404001 | 0.81 | MTNR1A (0.58) | MTNR1AP2RX7ATMNQO2CDYL | |
| SCHEMBL28561400 | 0.81 | MAPT (0.60) | MTNR1AP2RX7TDP1KDM4E | |
| SCHEMBL7340131 | 0.80 | TDP1 (0.58) | MTNR1AP2RX7NQO2CDYLTDP1 | |
| SCHEMBL5707320 | 0.80 | MAPT (0.62) | MTNR1AP2RX7KDM4E | |
| SCHEMBL30498970 | 0.80 | CDYL (0.60) | MTNR1AATMNQO2CDYLTDP1 | |
| SCHEMBL6615856 | 0.80 | CDYL (0.60) | MTNR1AATMNQO2CDYLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556361-A2 | 2-ALKYL-(2-AMINO-3-ARYL-PROPIONYL)-PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004037797-A2 | 2 - ALKYL - (2 - AMINO - 3 - ARYL - PROPIONYL) - PIPERAZINE DERIVATIVES AND RELATED COMPOUNDS AS MELANOCORTIN RECEPTOR LIGANDS FOR THE TREATMENT OF OBESITY | THE PROCTER & GAMBLE COMPANY (US) | 2004-05-06 | — | — | WO | claimed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| EP-3603648-A1 | COMPLEX OF NUCLEIC ACID MEDICINE AND MULTIBRANCHED LIPID | Shionogi & Co., Ltd (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237784-A1 | 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS | DCLRE1A, AZI2, CHD9 | MTNR1A 3582/4885MTNR1B 3246/4885P2RX7 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.